All the products on Naturvitae.com are "HEF". To learn more, click here.
Why should I purchase Pau d'arco? To learn more, click here.
Ingredients: 100% pure pau d'arco (Tabebuia impetiginosa) bark extracted in distilled water and 40% ethanol, using an extraction mehod tha provides the equivalent of approximately 500 mgs of pau d'arco bark per milliliter of extract.
Suggested Use: As dietary supplement, take 60 drops 2 or more times daily or as directed by a health care professional.
Contraindications: Not to be used during pregnancy or while breast-feeding.
Drug Interactions: None reported.
Other Observations: Large single dosages of pau d'arco decoctions may cause gastrointestinal upset and/or nausea. Do not use in high doses unless under the advice of a qualified health practitioner; reduce dosage if nausea occurs.
Also suggested:
- A-F,a proprietary blend of Rainforest botanicals used as folk remedies against fungi and yeast infections
- Jatobà Extract, an herb from the Amazon used by shamans for cystitis and Candida
- Graviola Max, a propreitary blend of Annona muricata and Annona montana
- Skin-P Support, 100% natural blend of Rainforest botanicals used by Shamans for skin roblems uch as psoriasis, eczema, dermatitis, rosacea, and as support to damaged and sensitive skins
Antimicrobial Actions (fungi, yeast, bacteria, and virus):
Pereira, E. M., et al. "Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis." Ann. Clin. Microbiol. Antimicrob. 2006 Mar; 5: 5.
Park, B. S., et al. "Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori." J. Ethnopharmacol. 2006 Apr; 105(1-2): 255-62.
Park, B. S., et al. “Selective growth-inhibiting effects of compounds identified in Tabebuia impetiginosa inner bark on human intestinal bacteria.” J. Agric. Food Chem. 2005 Feb; 23;53(4): 1152-7.
Park, B. S., et al. “Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori.” J. Ethnopharmacol. 2005 Dec;
Machado, T. B., et al. “In vitro activity of Brazilian medicinal plants, naturally occurring naphthoquinones and their analogues, against methicillin-resistant Staphylococcus aureus.” Int. J. Antimicrob. Agents. 2003; 21(3): 279-84.
Portillo, A., et al. “Antifungal activity of Paraguayan plants used in traditional medicine.” J. Ethnopharmacol. 2001; 76(1): 93–8.
Nagata, K., et al. “Antimicrobial activity of novel furanonaphthoquinone analogs.” Antimicrobial Agents Chemother. 1998; 42(3): 700–2.
Binutu, O. A., et al. “Antimicrobial potentials of some plant species of the Bignoniaceae family.” Afr. J. Med. Sci. 1994; 23(3): 269–73.
Giuraud, P., et al. “Comparison of antibacterial and antifungal activities of lapachol and b-lapachone.” Planta Med. 1994; 60: 373–74.
Li, C. J., et al. “Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.” Proc. Nat’l. Acad. Sci. USA 1993; 90(5): 1839–42.
Anesini, C., et al. “Screening of plants used in Argentine folk medicine for antimicrobial activity.” J. Ethnopharmacol. 1993; 39(2): 119–28.
Lagrota, M., et al. “Antiviral activity of lapachol.” Rev. Microbiol. 1983; 14: 21–6.
Gershon, H., et al. “Fungitoxicity of 1,4-naphthoquinonoes to Candida albicans and Trichophyton menta grophytes.” Can. J. Microbiol. 1975; 21: 1317–21.
Linhares, M. S., et al. “Estudo sobre of efeito de substancias antibioticas obitdas de Streptomyces e vegatais superiores sobre o herpesvirus hominis.” Revista Instituto Antibioticos, Recife 1975; 15: 25–32.
Anticancerous & Antileukemic Actions:
Larsson, D. E., et al. "Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines." Anticancer Res. 2006 Nov-Dec; 26(6B): 4125-9.
Bey, E. A., et al. "Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses." J. Cell Physiol. 2006 Dec; 209(3): 604-10.
Kung, H. N., et al. "Involvement of NO/cGMP signaling in the apoptotic and anti-angiogenic effects of beta-lapachone on endothelial cells in vitro." J. Cell Physiol. 2006 Dec 27;
Bentle, M. S., et al. "Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair." J. Biol. Chem. 2006 Nov; 281(44): 33684-96.
Sun, X., et al. "Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway." Cell Cycle. 2006 Sep; 5(17): 2029-35.
Woo, H. J., et al. "Beta-lapachone, a quinone isolated from Tabebuia avellanedae, induces apoptosis in HepG2 hepatoma cell line through induction of Bax and activation of caspase." J. Med. Food. 2006 Summer; 9(2):161-8.
Suzuki, M., et al. "Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro." Radiat. Res. 2006; 165(5): 525-31.
Lee, J. I., et al. "Beta-lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases." Exp. Oncol. 2006 Mar; 28(1): 30-5.
Lee, J. H., et al. “Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells.” Pharmacol. Res. 2005; 51(6): 553-60.
Reinicke, K. E., et al. “Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.” Clin. Cancer Res. 2005 Apr; 11(8): 3055-64.
Woo, H. J., et al. “Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity.” Int. J. Oncol. 2005; 26(4): 1017-23.
Park, H. J., et al. “Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.” Clin. Cancer Res. 2005 Dec; 11(24 Pt 1): 8866-71.
Balassiano, I. T., et al. “Demonstration of the lapachol as a potential drug for reducing cancer metastasis. Oncol. Rep. 2005; 13(2): 329-33.
Ough, M., et al. "Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1." Cancer Biol. Ther. 2005 Jan; 4(1): 95-102.
Park, H. J., et al. "Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation." Int. J. Radiat. Oncol. Biol. Phys. 2005 Jan; 61(1): 212-9.
Kumi-Diaka, J., et al. "Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and beta-lapachone combination treatment." Cancer Cell Int. 2004 Aug; 4(1): 5.
Choi, B. T., et al. “beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells.” Anticancer Drugs. 2003 Nov; 14(10): 845-50.
Renou, S. G., et al. “Monoarylhydrazones of alpha-lapachone: synthesis, chemical properties and antineoplastic activity.” Pharmazie. 2003 Oct; 58(10): 690-5.
Choi, Y. H., et al. “Suppression of human prostate cancer cell growth by beta-Lapachone via down-regulation of PRB phosphorylation and induction of Cdk Inhibitor p21(WAF1/CIP1).” J. Biochem. Mol. Biol. 2003 Mar; 36(2): 223-9.
Colman de Saizarbitoria, T., et al. “Bioactive furonaphtoquinones from Tabebuia barbata (Bignoniaceae).” Acta Cient. Venez. 1997; 48(1): 42-6.
Ueda, S., et al. “Production of anti-tumour-promoting furanonaphthoquinones in Tabebuia avellanedae cell cultures.” Phytochemistry. 1994 May; 36(2): 323-5.
Schuerch, A. R., et al. “B-Lapachone, an inhibitor of oncornavirus reverse transcriptase and eukarotic DBA Polymerase-A. Inhibitory effect, thiol dependency and specificity.” Eur. J. Biochem. 1978; 84: 197–205.
Linardi, M. D. C., et al. “A lapachol derivative active against mouse lymphocyte leukemia P-388.” J. Med. Chem. 1975; 18(11): 1159–62.
Block, J. B., et al. “Early clinical studies with lapachol (NSC-11905).” Cancer Chemother. Rep. 1974; 4: 27–8.
Santana, C. F., et al. “Preliminary observation with the use of lapachol in human patients bearing malignant neoplasms.” Revista do Instituto de Antibioticos 1971; 20: 61–8.
Rao, K. V., et al. “Recognition and evaluation of lapachol as an antitumor agent.” Canc. Res. 1968; 28: 1952–54.
Anti-inflammatory & Pain-Relieving Actions:
Awale, S., et al. ”Nitric oxide (NO) production inhibitory constituents of Tabebuia avellanedae from Brazil.” Chem. Pharm. Bull. 2005; 53(6): 710-3.
Lee, J. H., et al. "Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells." Pharmacol. Res. 2005; 51(6): 553-60.
de Miranda, F. G., et al. “Antinociceptive and antiedematogenic properties and acute toxicity of Tabebuia avellanedae Lor. ex Griseb. inner bark aqueous extract.” BMC. Pharmacol. 2001; 1(1): 6.
Oga, S., et al. “Toxicidade e atividade anti-inflamatoria de Tabebuia avellanedae Lorentz (‘Ipe Roxo’).” Rev. Fac. Farm. Bioquim. 1969; 7: 4.
Antipsoriatic Actions:
Muller, K., et al. “Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.” J. Nat. Prod. 1999; 62(8): 1134–36.
Antioxidant Actions:
Park, B. S., et al. “Antioxidant activity and characterization of volatile constituents of Taheebo (Tabebuia impetiginosa Martius ex DC).” J. Agric. Food Chem. 2003; 51(1): 295-300.
Antivenin Actions:
Nunez, V., et al. “Neutralization of the edema-forming, defibrinating and coagulant effects of Bothrops asper venom by extracts of plants used by healers in Colombia.” Braz. J. Med. Biol. Res. 2004; 37(7): 969-77.
Otero, R., et al. “Snakebites and ethnobotany in the northwest region of Colombia. Part III: neutralization of the haemorrhagic effect of Bothrops atrox venom.” J. Ethnopharmacol. 2000 Nov; 73(1-2): 233-41.
Otero, R., et al. “Snakebites and ethnobotany in the northwest region of Colombia: Part II: neutralization of lethal and enzymatic effects of Bothrops atrox venom.” J. Ethnopharmacol. 2000 Aug; 71(3): 505-11.
Anti-Parasitic & Anti-Malarial Actions:
Ferreira, V. F., et al. "Trypanocidal agents with low cytotoxicity to mammalian cell line: a comparison of the theoretical and biological features of lapachone derivatives." Bioorg. Med. Chem. 2006 Aug; 14(16): 5459-66.
Silva, R. S., et al. "Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi." Eur. J. Med. Chem. 2006 Apr; 41(4): 526-30.
Menna-Barreto, R. F., et al. "Effect of a beta-lapachone-derived naphthoimidazole on Trypanosoma cruzi: identification of target organelles." J. Antimicrob. Chemother. 2005 Dec; 56(6): 1034-41.
Perez-Sacau, E., et al. "Antiplasmodial activity of naphthoquinones related to lapachol and beta-lapachone." Chem. Biodivers. 2005; 2(2): 264-74.
Lima, N. M., et al. "Antileishmanial activity of lapachol analogues." Mem. Inst. Oswaldo Cruz. 2004 Nov; 99(7): 757-61.
de Andrade-Neto, V. F., et al. "Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo." Bioorg. Med. Chem. Lett. 2004 Mar; 14(5): 1145-9.
Pinto, C. N., et al. “Chemical reactivity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy.” Arzneimittelforschung. 2000; 50(12): 1120-8.
Austin, F. R. “Schistosoma mansoni chemoprophylaxis with dietary lapachol.” Am. J. Trop. Med. Hyg. 1979; 23: 412–19.
Gilbert, B., et al. “Schistosomiasis. Protection against infection by terpenoids.” An. Acad. Brasil. Cienc. 1970; 2 (Suppl): 397–400.
WARNINGS: Information, statements and products on this website have not been evaluated by the FDA and are not intended to diagnose, mitigate, treat, cure, or prevent any disease or health condition. The natural properties of the botanicals are only referred to their common uses among folk and herbal traditions. Our products are not intended to diagnose, cure, or prevent any disease as well. It's not meant to give any suggestion of diagnosis or disesase treatment. Please see a doctor when needed.